Oliver Pohl

No ORCID on file · 5 papers in corpus · active 2013-2021

Study types

  • article 5

Condition tags

  • dysmenorrhea 1
  • mesh:D004715 1
  • endometriosis 1
  • mesh:D017699 1
  • mesh:D004412 1
article 2021
A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
British journal of clinical pharmacology ·doi:10.1111/bcp.15171

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-pha…

article 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z
article 2017
Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109
·doi:10.1210/jc.2017-01875

Context: OBE2109 is a potent, oral gonadotropin-releasing hormone receptor antagonist being developed for the treatment of sex-hormone-dependent diseases in women. Objective: We assessed the pharmacodynamics and safety of OBE2109 alone and …

article 2014
Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114522526
article 2013
Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate
·doi:10.1111/jcpt.12098

WHAT IS KNOWN AND OBJECTIVE: Ulipristal acetate (UPA) is a novel selective progesterone receptor modulator for the treatment of benign gynaecological conditions such as uterine myoma. In vitro, it is mainly metabolized by the cytochrome P45…